Resumo
Polycystic Ovary Syndrome (PCOS) is the most common endocrine-metabolic pathology among women at reproductive age. It has a multifactorial character, and its etiology has not yet been precisely explained. The pathogenesis of PCOS is related to metabolic issues such as hyperandrogenism and insulin resistance, and is also associated with obesity, type 2 diabetes and increased cardiovascular risk. Manifestations such as irregular menstruation, acne, hisurtism and androgenic alopecia are common in addition to the consequent psychological and quality of life impacts. Thus, knowing that the adoption of healthy habits have therapeutic impacts in the face of various signs and symptoms of PCOS, there is a need to analyze the influence of lifestyle on the prognosis of PCOS. The present study carried out its searches in the PUBMED database, using the descriptors "polycystic ovary syndrome", "life style" and "prognosis", using the Boolean operator "and". Inclusion criteria were used: articles written in Portuguese, English and Spanish, published in the last 5 years. 19 results were obtained, 5 of which were excluded, resulting in 14 articles chosen for theoretical reference. The influence of lifestyle on the prognosis of PCOS is notorious, especially in patients with overweight and obesity. Thus, healthy behaviors have the potential to improve pathological conditions and bad habits demonstrate that they can induce clinical manifestations of PCOS in predisposed people. Lifestyle changes, mainly associated with weight loss, show improvements in aspects such as insulin resistance, free testosterone, acne, hirsutism and reproductive function, reduced cardiovascular risk, in addition to positively influence to the psychic and quality of life in analyzed patients. Therapeutic strategies that combine lifestyle changes and drug interventions have been shown to be more effective, as well as strategies structered with the monitoring of professionals tend to increase adherence to treatment.
Referências
BAHRI KHOMAMI, M. et al. Lifestyle and pregnancy complications in polycystic ovary syndrome: The SCOPE cohort study. Clinical Endocrinology, [s. l.], v. 90, n. 6, p. 814–821, 2019. Available at: https://doi.org/10.1111/cen.13954
DOKRAS, A. et al. Weight loss and lowering androgens predict improvements in health-related quality of life in women with PCOS. Journal of Clinical Endocrinology and Metabolism, [s. l.], v. 101, n. 8, p. 2966–2974, 2016. Available at: https://doi.org/10.1210/jc.2016-1896
GLINTBORG, D.; ANDERSEN, M. Morbidity in polycystic ovary syndrome. European Journal of Endocrinology, [s. l.], v. 176, n. 2, p. R53–R65, 2017. Available at: https://doi.org/10.1530/EJE-16-0373
JIN, P.; XIE, Y. Treatment strategies for women with polycystic ovary syndrome. Gynecological Endocrinology, [s. l.], v. 34, n. 4, p. 272–277, 2018. Available at: https://doi.org/10.1080/09513590.2017.1395841
JISKOOT, G. et al. Long-term effects of a three-component lifestyle intervention on emotional well-being in women with Polycystic Ovary Syndrome (PCOS): A secondary analysis of a randomized controlled trial. PLoS ONE, [s. l.], v. 15, n. 6, p. 1–16, 2020. Available at: https://doi.org/10.1371/journal.pone.0233876
KHATLANI, K.; NJIKE, V.; COSTALES, V. C. Effect of Lifestyle Intervention on Cardiometabolic Risk Factors in Overweight and Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Metabolic Syndrome and Related Disorders, [s. l.], v. 17, n. 10, p. 473–485, 2019. Available at: https://doi.org/10.1089/met.2019.0049
LIM, S. et al. Barriers and facilitators to weight management in overweight and obese women living in Australia with PCOS: A qualitative study. BMC Endocrine Disorders, [s. l.], v. 19, n. 1, p. 1–9, 2019. Available at: https://doi.org/10.1186/s12902-019-0434-8
OBERG, E. et al. Psychological well-being and personality in relation to weight loss following behavioral modification intervention in obese women with polycystic ovary syndrome: a randomized controlled trial. European Journal of Endocrinology, [s. l.], v. 183, n. 1, p. 1–11, 2020. Available at: https://doi.org/10.1530/EJE-20-0066
OSIBOGUN, O.; OGUNMOROTI, O.; MICHOS, E. D. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. Trends in Cardiovascular Medicine, [s. l.], v. 30, n. 7, p. 399–404, 2020. Available at: https://doi.org/10.1016/j.tcm.2019.08.010
PARKER, M. et al. Adherence to treatment for polycystic ovarian syndrome: A systematic review. PLoS ONE, [s. l.], v. 15, n. 2, p. 1–12, 2020. Available at: https://doi.org/10.1371/journal.pone.0228586
WANG, A. et al. The effectiveness of metformin, oral contraceptives, and lifestyle modification in improving the metabolism of overweight women with polycystic ovary syndrome: a network meta-analysis. Endocrine, [s. l.], v. 64, n. 2, p. 220–232, 2019. Available at: https://doi.org/10.1007/s12020-019-01860-w
WITCHEL, S. F.; TEEDE, H. J.; PEÑA, A. S. Curtailing PCOS. Pediatric Research, [s. l.], v. 87, n. 2, p. 353–361, 2020. Available at: https://doi.org/10.1038/s41390-019-0615-1
YOUNG, L.; CHO, L. Unique cardiovascular risk factors in women. Heart, [s. l.], v. 105, n. 21, p. 1656–1660, 2019. Available at: https://doi.org/10.1136/heartjnl-2018-314268
ZHANG, B. et al. Lifestyle and environmental contributions to ovulatory dysfunction in women of polycystic ovary syndrome. BMC Endocrine Disorders, [s. l.], v. 20, n. 1, p. 1–7, 2020. Available at: https://doi.org/10.1186/s12902-020-0497-6